Global Healthcare Company
Leading Innovative Precision Medicines
for Unmet Medical Needs
Global Healthcare Company
Leading Innovative Precision Medicines
for Unmet Medical Needs
Our Key
Therapeutic
Areas
Strategic R&D investments
for innovative pharmaceutical development
PRESS RELEASE
-
Dong-A ST highlights oncology, immunology pipelines at BIO USA 2026
2026.07.01. Dong-A ST said Wednesday that it showcased its research and development (R&D) achievements and key pipeline assets at the BIO International Convention 2026 (BIO USA 2026), held in San Diego, California, from June 22 to 25.It also held a series of business meetings to attract investment, secure licensing opportunities and strengthen global partnerships.At the event, the company highlighted its pipeline in oncology, immunology and inflammatory diseases, and neurodegenerative disorders, along with its biosimilar business, as it sought global partners for licensing and co-development. Dong-A ST also held strategic meetings with global pharmaceutical companies and biotech firms to expand collaboration opportunities as its key R&D programs advance. In parallel, the company pursued open innovation initiatives to identify promising assets for in-licensing, ranging from early-stage research projects to clinical-stage candidates.Among the company's featured assets were DA-4701, an EGFR-targeted protein degrader; DA-4531, a PARP7 inhibitor; and DA-3880, a biosimilar of the erythropoiesis-stimulating agent NESP, or Novel Erythropoiesis Stimulating Protein.DA-4701 is an EGFR PROTAC candidate based on targeted protein degradation (TPD) technology and is being developed to overcome resistance associated with existing third-generation EGFR inhibitors.The candidate employs an inhibitor targeting the EGFR allosteric binding site, providing high selectivity for mutant EGFR over the wild-type receptor. It also incorporates a dual-mode mechanism that combines targeted protein degradation with EGFR inhibition. By suppressing aberrant EGFR signaling while recruiting an E3 ligase to degrade the target protein, DA-4701 is expected to deliver enhanced anticancer activity.In preclinical studies, DA-4701 demonstrated potent activity against EGFR L858R/C797S mutations and showed promising synergistic effects when combined with amivantamab. The candidate also demonstrated strong activity in patient-derived cells and organoids, with an improved skin safety profile compared with osimertinib.DA-4531 is an orally administered, selective PARP7 inhibitor designed to suppress tumor cell survival while simultaneously activating antitumor immune responses. PARP7 is known to promote cancer cell growth and help tumors evade immune surveillance.The candidate induces direct tumor cell death by disrupting DNA damage repair mechanisms while activating Type I interferon (IFN) signaling to restore the tumor microenvironment (TME) and enhance immune cell activity. Preclinical studies demonstrated robust antitumor efficacy as monotherapy, with even greater activity when combined with anti-PD-1 immunotherapy. DA-4531 also showed promising efficacy in tumor models resistant to anti-PD-1 treatment.DA-3880 is a biosimilar of the erythropoiesis-stimulating agent NESP. The product was commercialized in Japan in 2019, demonstrating the company's manufacturing capabilities and product competitiveness.A phase 1 clinical trial using Aranesp, the European reference product, confirmed biosimilarity, and Dong-A ST is preparing additional development programs to support entry into the U.S. and European markets. The company plans to hold scientific advice meetings with the U.S. Food and Drug Administration (FDA) and the European Medicines Agency (EMA) while seeking global partners for co-development and commercialization in both regions.Dong-A ST said it plans to leverage BIO USA 2026 to expand global partnerships, pursue out-licensing and co-development opportunities for its innovative drug pipeline, strengthen its R&D capabilities through open innovation and further accelerate its expansion into global markets.Source: Korea Biomedical Review(https://www.koreabiomed.com)
2026-09-03
-
Dong-A ST to Build AI Drug Discovery Platform, Targets First Version This Year
2026.06.23. Dong-A ST is launching efforts to build its own artificial intelligence (AI) drug discovery platform. The strategy aims to improve research efficiency by actively using AI in the candidate discovery process and, over the long term, to internalize its drug development capabilities.Oh Yoon-seok, chief science officer (CSO) at Dong-A ST, met with reporters at the BIO International Convention (BIO USA) held in San Diego on Sunday. "We are developing an AI platform together with DAI, an IT specialist among our affiliates," he said. "Around the end of the year, we plan to unveil the first version of the platform that internal researchers can use and conduct beta testing."The platform currently under development focuses on upgrading an AI-based candidate screening algorithm, previously used by only some researchers, so that any researcher can use it. While the existing system was operated mainly by researchers capable of coding, the plan is to build a dashboard-based user environment to improve accessibility and versatility."We previously had a system that discovered candidates using structure-based algorithms, but only some researchers could use it," Oh said. "We are developing it into a user-friendly platform so that researchers can use it more easily."Dong-A ST is currently using AI to select candidates from compound libraries and evaluate their potential to bind with specific target proteins. Although the scope of use is still in an early stage, the company expects that once the platform is complete, more researchers will be able to participate in drug candidate discovery using AI.Oh did not rule out the possibility of cooperation with external AI drug discovery companies. However, the focus is on securing internal competitiveness rather than relying on external sources for AI capabilities. "To sustain drug development over the long term, an in-house system is needed," Oh stressed. "Even when using external platforms, internal expertise that can understand and operate them must absolutely be in place."He also left open the possibility of acquiring a company with AI technology. "If there is an appropriate opportunity, we could consider acquiring a related company," he said, while adding, "For now, we are focused on upgrading the platform based on existing algorithms and prototypes."The company also plans to review the possibility of commercialization if the platform's performance is verified. "If sufficient verification is conducted internally and competitiveness is proven, a business model would be possible, such as conducting joint research with external companies or providing candidate discovery services for specific targets," Oh forecast.Source : https://en.sedaily.com/finance/2026/06/23/dong-a-st-to-build-ai-drug-discovery-platform-targets-first
2026-09-03
-
[AACR] Dong-A ST and Aptis present 9 anticancer candidates, including ADCs
2026.03.31 Dong-A ST announced on March 25 that, in collaboration with its ADC-specialized subsidiary AbTis, it will present a total of nine anticancer research findings at the American Association for Cancer Research (AACR 2026), scheduled to take place in San Diego, USA, from April 17 to 22 (local time).At AACR 2026, Dong-A ST plans to present preclinical anticancer research outcomes encompassing diverse mechanisms of action, including a PARP7 inhibitor under in-house development, an epidermal growth factor receptor (EGFR)-targeted protein degrader (TPD) co-developed with HK inno.N, and a bispecific ADC being co-developed with AbTis.Regarding PARP7 inhibitors, two poster presentations are scheduled. These include a novel PARP7 inhibitor designed to induce immune activation and inhibit tumor growth, as well as a PARP7 inhibitor with a dual mechanism of action demonstrating potent antitumor efficacy.Dong-A ST emphasized that preclinical studies have demonstrated that its novel PARP7 inhibitor candidates under development exert potent anticancer effects by concurrently inducing immune activation and suppressing tumor growth. The company further noted that one such candidate showed strong efficacy as a monotherapy and achieved complete remission (CR) when used in combination with anti-PD-1 antibodies or standard chemotherapy.In addition, Dong-A ST will present two poster sessions on EGFR-targeted TPD co-developed with HK inno.N. These include data on the antitumor activity and safety of a mutation-selective EGFR degrader (SC3613) targeting patients with EGFR-mutated non-small cell lung cancer (NSCLC) who are resistant to tyrosine kinase inhibitors (TKIs), as well as an allosteric EGFR degrader (SC3499) designed to overcome resistance to Tagrisso(osimertinib).In preclinical studies, SC3613 selectively degraded mutant EGFR, inducing immune activation alongside potent tumor suppression, and demonstrated a significantly reduced incidence of dermatologic adverse events with improved tolerability compared to osimertinib. In addition, SC3499, based on its high specificity for selectively degrading mutant EGFR, exhibited potent anticancer activity by maintaining efficacy against a range of resistance-associated mutations to osimertinib, even with just once-daily oral administration.Five poster presentations will address dual-antibody ADC anticancer candidates being co-developed with AbTis. Specifically, these include the evaluation of immune-mediated antitumor activity and potential for combination with immunotherapies for ‘DA-3501’ (development code), a CLDN-18.2-targeted ADC;bispecific antibody ADCs targeting NECTIN-4 and PD-L1, designed to integrate immune checkpoint inhibition with targeted cytotoxicity for urothelial carcinoma and lung squamous cell carcinoma; approaches to overcoming tumor heterogeneity in gastric cancer using eKiH-based CLDN18.2 and human epidermal growth factor receptor 2 (HER2) bispecific ADCs; strategies to overcome resistance in solid tumors through eKiH-based HER2 and AXL bispecific ADCs; and enhanced targeting of heterogeneous tumors via bispecific ADCs utilizing an improved heteromerization platform and precision payload conjugation technologies.According to Dong-A ST, preclinical studies demonstrated that DA-3501 (AT-211) exhibited potent immune-mediated antitumor activity in a gastric cancer patient model resistant to existing antibody therapies. Furthermore, a bispecific ADC targeting NECTIN4 and PD-L1, developed using the company’s proprietary bispecific ADC platform, showed potential to overcome the limitations associated with conventional combinations of antibodies and immune checkpoint inhibitors.In addition, bispecific ADCs targeting CLDN18.2 and HER2, as well as HER2 and AXL, demonstrated potential to address challenges related to therapeutic resistance and target heterogeneity. The bispecific ADC platform developed by Dong-A ST using AbTis’s ‘Abclick’ platform enables the simultaneous targeting of clinically relevant antigen combinations, thereby achieving more potent and sustained antitumor effects compared to single-target ADCs.Through this presentation, Dong-A ST and AbTis aim to highlight their research capabilities and platform competitiveness in the field of anticancer therapeutics on the global stage, while actively pursuing diverse partnership opportunities. "This presentation at AACR will serve as an opportunity to demonstrate our research capabilities globally, based on our anticancer pipelines with diverse mechanisms and precision-targeted therapy strategies. Through our collaboration with AbTis, we will continue to expand our portfolio of next-generation anticancer drugs, including bispecific ADCs,"a Dong-A ST official said.Source : [AACR] Dong-A ST and Aptis present 9 anticancer candidates, including ADCs < ENGLISH NEWS < 기사본문 - 더바이오
2026-05-18
LOCATION
Please check our location information
- Corporate Headquarters
-
64, Cheonho-daero, Dongdaemun-gu, Seoul
Tel. 02-920-8111
- Research Headquarters
(Yong-in) -
21, Geumhwa-ro 105beon-gil, Giheung-gu, Yongin-si, Gyeonggi-do
Tel. 031-280-1400
- Research Headquarters
(Song-do) -
45, Jisikgiban-ro, Yeonsu-gu, Incheon
Tel. 032-610-0300